Search

A facile and sensitive electrochemical sensor for determining imatinib (IMA) was constructed by modifying a glassy carbon electrode (GCE) with a nanocarbon material, acetylene black (AB). The electrochemical behavior of IMA on the prepared GCE/AB was studied using electrochemical techniques, namely, differential pulse voltammetry (DPV) and electrochemical impedance spectroscopy. The direct determination of IMA by the GCE/AB sensor was accomplished using DPV under optimized conditions. The method verification showed that the oxidation peak current was proportional to the concentrations of IMA in the linear ranges of 0.01–0.5 and 0.5–4 μM, with correlation coefficients of 0.9856 and 0.9946, respectively. The limit of detection of the GCE/AB sensor was 0.15 nM. Moreover, the GCE/AB sensor showed good precision and accuracy. Finally, the GCE/AB sensor was successfully applied to determine IMA in human serum samples, and the recoveries were satisfactory. [ABSTRACT FROM AUTHOR]

A novel electrochemical sensor for the determination of triclosan (TCS) based on acetylene black (AB)/carbon nanotube (CNT)/cetyl sulphonyl betaine (SB16) was prepared. The composite AB/CNT/SB16 sensor was constructed using AB electrode with CNT and SB16 as sensitising materials. Sensor performance was evaluated by cyclic voltammetry, scanning electron microscopy and electrochemical impedance spectroscopy analyses. The linear equation was Ip(μA) = 19.16CTCS(μM) + 0.1319(R2 = 0.9823), and the linear range of the prepared method for the detection of TCS was from 0.01 μM to 2.0 μM with a detection limit of 6.18 nM. The sensor also displayed excellent selectivity, repeatability, and stability for TCS determination. Finally, the sensor was successfully used to detect TCS in real commodity samples, with a relative standard deviation from 0.56% to 2.32%, consistent with the results of high-performance liquid chromatography. [ABSTRACT FROM AUTHOR]

Carbohydrate antigen 50 (CA50) is initially reported as a cancer-specific antigen expressed on the surface of human colorectal Colo-205 cancer cells. Subsequently, increased serum CA50 levels are observed in patients not only with colorectal cancers but also other types of cancers. Eventually, serum CA50 is measured clinically as a cancer biomarker. However, serum CA50 level does not always increase in cancer patients but does increase in patients suffering from nonneoplasm diseases, which indicates that serum CA50 is not produced by cancer cells exclusively. Therefore, the serum CA50 levels in patients suffering different types of diseases should be systematically compared in order to comprehend the molecular nature of serum CA50 as a biomarker. In our current study, we measured and analyzed serum CA50 levels from 2113 patients with 14 clinically defined diseases with at least 30 independent tests for each disease in addition to 13,997 serum samples from individuals who attend their annual physical examination as healthy controls. Based on the mean, median, and -Log 10 p values, we found that patients suffering from pancreatic cancer, cirrhosis, pancreatitis, lung cancer, type 2 diabetes mellitus, and colon cancer had highest levels of serum CA50 while patients suffering from coronary heart disease, gastric cancer, and rectum cancer showed comparable serum CA50 levels to that of healthy controls. Moreover, patients with osteoporosis, anemia, or gastritis had lower serum CA50 levels than that of healthy controls. Furthermore, healthy individuals older than 65 years old had increased serum CA50 levels compared with that of healthy controls. Taken together, these data suggest that serum CA50 is likely to be a system malfunction biomarker, and the serum CA50 levels could be used as diagnostic biomarkers not only for cancers but also for other nonneoplasm diseases., (© 2019 Elsevier Inc. All rights reserved.)

Lentinula edodes has been used to improve general health for thousands of years in Asia. It is the second largest cultivated and the most popular edible mushroom in the world known as "Xianggu" in China and "Shiitake" in Japan. Lentinan is a polysaccharide extracted from Lentinula edodes. β-Glucan is the major bioactive component in lentinan with immunostimulatory effect. The antitumor property of lentinan was reported in 1960s. Biochemical studies indicate that immunocytes can be activated by lentinan through multiple signaling pathways, such as TLR4/Dectin1-MAPK and Syk-PKC-NFκB pathways. Though it has been approved as an adjuvant therapeutic drug both in China and Japan for treating cancers since 1980s, a systematic review of clinical studies of lentinan has not been conducted elaborately. In this review, over 9474 reported lentinan-associated cancer treatment cases are evaluated and summarized from 135 independent studies in China during the past 12 years (2004-2016) based on CNKI (China National Knowledge Infrastructure), VIP (Chongqing VIP Chinese Scientific Journals Database) and Wanfang database. The 9474 reported lentinan-associated cancer treatment cases include lung cancer (3469 cases), gastric cancer (3039 cases), colorectal cancer (1646 cases), ovarian cancer (183 cases), cervical cancer (130 cases), Non-Hodgkin lymphoma (70 cases), pancreatic cancer (15 cases), cardiac cancer (15 cases), nasopharyngeal cancer (14 cases), duodenal cancer (1 case) and 110 cancer cases with no classifying patient information. Overall clinical data show solid effect of lentinan on improving the quality of life and on promoting the efficacy of chemotherapy and radiation therapy during cancer treatment., (© 2019 Elsevier Inc. All rights reserved.)

Most of clinically used cancer biomarkers are either specific glycan structures or glycoproteins. Although the high serum levels of the cancer biomarkers are also present in certain patients suffering noncancer diseases, systematic measurement and comparison of the serum levels of all cancer biomarkers among cancer and noncancer patients have not been reported. In this study, the serum levels of 17 glucose and glycan-related biomarkers including 10 cancer biomarkers SCCA, CA724, CA50, CA242, CA125, CA199, CA153, AFP, CEA, and PSA were retrospectively investigated based on clinical laboratory data in two medical centers during the past 6 years (2012-2018). The data included a total of 1,477,309 clinical lab test results of 17 biomarkers from healthy controls and patients suffering 64 different types of cancer and noncancer diseases. We found that the median serum levels of CA724, CEA, CA153, SCCA, and CA125 were highest not in cancer patients but in patients suffering gout, lung fibrosis, nephrotic syndrome, uremia, and cirrhosis, respectively. Consistently, the classical ovarian cancer biomarker CA125 had better overall sensitivity and specificity as biomarker for cirrhosis (67% and 92%, respectively) than that for ovarian cancer (41% and 97%, respectively). Furthermore, the information shown as heatmap or waterfall built on the -Log 10 p values of the 17 glycan-related biomarkers in different clinically defined diseases suggested that all glycan-related biomarkers had cancer-, aging-, and disease-relevant characteristics and cancers were systems disease. The detailed presentation of the data for each of the 17 biomarkers will be deliberated in chapters 6-23 in this book series., (© 2019 Elsevier Inc. All rights reserved.)

Tim-3 is considered as one of the T-cell immunoglobulin mucin (TIM) gene family members, which contributes to the activating or silencing genes, but the mechanism of Tim-3 function in mediating SLE or tumor metastasis has not been well explored. Here, we reported Tim-3 was high expressed in the peripheral blood mononuclear cells (PBMCs) of patients with SLE, detected by RT-PCR, significantly, GATA-3 mRNA expression also increased in patients with SLE, compared with the healthy control groups. The bioinformatics used to detect the TCGA database indicated the abnormal expression of Tim-3 was involved in several different cancer types. Further, the higher expression of Tim-3 in kidney renal clear cell carcinoma TCGA database indicated it was a marker for worse 5-year survival. The high expression of Tim-3 in different ccRCC cell lines was detected in both RNA level and protein level. Further, two kinds of relative Tim-3 siRNAs in ccRCC cell lines inhibit cell migration and invasion in vitro, However, the inhibition could be partially rescued by the additional GATA3 knockdown. Further, the down regulation in the RNA and protein levels of GATA3, and the negative correlation between Tim-3 and GATA3 implied that suppression of downstream GATA3 was an important mechanism by which Tim-3 triggered metastasis in ccRCC cell lines. Together, our experiments reveal the role for Tim-3 in facilitating SLE or invasive potential of ccRCC cells by either activating GATA3 or inhibiting GATA3, suggesting that Tim-3 might be a potential therapeutic target for treating SLE or clear cell renal cell carcinoma.